Full-Time

Scientist – Preclinical Team

Preclinical

Capricor Therapeutics

Capricor Therapeutics

201-500 employees

Biotech developing cell- and exosome therapeutics

Compensation Overview

$95k - $115k/yr

San Diego, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Pharmacology
Requirements
  • Ph.D. in a relevant scientific discipline with expertise in nonclinical operations within drug discovery and development.
  • Hands-on experience with cell biology techniques, including RNA/DNA extraction, PCR, Western blot, ELISA, and interventional assays for small molecules and biologics.
Responsibilities
  • Partner with the Principal Scientist and Director to provide preclinical expertise, including animal handling and study design.
  • Plan, execute, and analyze in vivo and ex vivo studies to support program objectives.
  • Perform cell-based assays and tissue analyses from in vivo studies; compile and report results.
  • Conduct survival surgeries and establish rodent models using aseptic techniques.
  • Develop, characterize, and implement new animal models to enhance pharmacology study effectiveness.
  • Maintain detailed, audit-ready documentation of all studies to ensure data integrity and traceability.
  • Optimize and implement best practices for in vivo research, including model selection, dosing strategies, and sample/data collection techniques.
  • Ensure compliance with regulatory guidelines and ethical standards for all preclinical activities.
  • Evaluate and integrate new technologies and platforms to improve study efficiency and quality.
  • Perform and interpret preclinical imaging studies (e.g., IVIS).
  • Contribute to a team culture that promotes continuous improvement, ownership, and inclusion.
Desired Qualifications
  • Experience across diverse therapeutic modalities (small molecules, biologics, nucleic acid therapeutics, gene therapy).
  • Familiarity with age-related disease models (inflammation, metabolic disorders, neurodegeneration, muscle atrophy, bone/joint deficits).
  • Experience with metabolic chambers, behavioral assays, and related data analysis.
Capricor Therapeutics

Capricor Therapeutics

View

Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.

Company Size

201-500

Company Stage

IPO

Headquarters

Beverly Hills, California

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval expected August 22, 2026 enables rapid market entry and revenue generation.
  • Manufacturing facility passed FDA pre-license inspection; capacity scales to 2,500 patients annually.
  • $318 million cash runway funds operations through Q4 2027 post-launch commercialization.

What critics are saying

  • FDA rejects Deramiocel BLA again by August 22, 2026 due to manufacturing deficiencies.
  • Sarepta's Elevidys gene therapy captures 80% DMD market share within 24 months.
  • EVP insider share sales signal management doubts; stock drops 50% pre-approval decision.

What makes Capricor Therapeutics unique

  • First therapy delivering statistically significant upper limb function improvement in DMD.
  • Rare Pediatric Disease Designation qualifies Capricor for valuable Priority Review Voucher.
  • Exclusive US and Japan commercialization partnership with Nippon Shinyaku validates market potential.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Capricor Therapeutics who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Staff Training (not in predefined)

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-3%
Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results

HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...